Phase 1 Pilot: Paclitaxel (tubulin inhibitor) and NALIRIFOX in PDAC with peritoneal carcinomatosis

This trial by the University of Colorado, Denver evaluates safety and early efficacy of combining intraperitoneal paclitaxel with intravenous NALIRIFOX, a multi-agent chemotherapy regimen, in adults with pancreatic ductal adenocarcinoma metastatic to the peritoneum. The study employs a biweekly 14-day cycle to assess treatment tolerance, tumor response through scans and labs, and the potential for conversion surgery, offering insights into a novel treatment strategy for advanced PDAC.